MDS-1497: Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes

作者：G. Garcia-Manero, U. Platzbecker, P. Fenaux, Gail J. Roboz, C. Fong, M. Hus, Robert Delage, A. Brunner, Je-Hwan Lee, Mehmet Turgut, D. Mazure, Yin-Hsun Feng, Yasushi Miyazaki, Z. Kořístek, S. Dimicoli-Salazar, M. Campelo, D. Lavie, D J Culligan, Grace Ku, Zhijian Xiao, Fang Fang, Maggie Headley, J. Potluri, A. Zeidan, Jacqueline S. Garcia · 发表于：Clinical Lymphoma, Myeloma & Leukemia · 年份：2025 · DOI：10.1016/s2152-2650(25)02083-x · 被引用次数：7